Latest Content

Delgocitinib led to notable improvement by week 4, which may have helped improve longer-term treatment adherence.

As physician shortages and burnout threaten the patient experience in oncology, The US Oncology Network works to scale solutions, including the use AI ambient scribes and other workflow fixes, as well as fostering self-care strategies.

At NAACOS 2026, value-based care leaders make the case for treating payers as partners and explain what providers must see in return.

A lengthy Ways and Means Committee hearing revealed extensive Medicare system exploitation and ignited partisan debates on fixing it.

Speakers at the NAACOS Spring 2026 Conference illustrated means of using technology in value-based care to implement preventive medicine.

New reports spotlight inequities—from Black maternal mortality to 988’s youth impact—as well as rising cancer risk and gaps in food aid.

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Mosunetuzumab, a bispecific, plus polatuzumab vedotin, an antibody-drug conjugate, deliver high response rates in relapsed MCL, potentially enabling outpatient community oncology treatment and wider patient access.